CN100558367C - 化合物在制备用于提高癌症治疗疗效的药物中的用途 - Google Patents

化合物在制备用于提高癌症治疗疗效的药物中的用途 Download PDF

Info

Publication number
CN100558367C
CN100558367C CNB028160037A CN02816003A CN100558367C CN 100558367 C CN100558367 C CN 100558367C CN B028160037 A CNB028160037 A CN B028160037A CN 02816003 A CN02816003 A CN 02816003A CN 100558367 C CN100558367 C CN 100558367C
Authority
CN
China
Prior art keywords
purposes
galectins
pectin
chemical compound
galectin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CNB028160037A
Other languages
English (en)
Chinese (zh)
Other versions
CN1543351A (zh
Inventor
张岩
V·萨塞克
Original Assignee
GlycoGenesys Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by GlycoGenesys Inc filed Critical GlycoGenesys Inc
Publication of CN1543351A publication Critical patent/CN1543351A/zh
Application granted granted Critical
Publication of CN100558367C publication Critical patent/CN100558367C/zh
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/732—Pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/10—Anthelmintics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
CNB028160037A 2001-06-21 2002-06-21 化合物在制备用于提高癌症治疗疗效的药物中的用途 Expired - Fee Related CN100558367C (zh)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US29999101P 2001-06-21 2001-06-21
US60/299,991 2001-06-21
US10/176,235 US6680306B2 (en) 2001-06-21 2002-06-20 Method for enhancing the effectiveness of cancer therapies
US10/176,235 2002-06-20

Publications (2)

Publication Number Publication Date
CN1543351A CN1543351A (zh) 2004-11-03
CN100558367C true CN100558367C (zh) 2009-11-11

Family

ID=26872020

Family Applications (1)

Application Number Title Priority Date Filing Date
CNB028160037A Expired - Fee Related CN100558367C (zh) 2001-06-21 2002-06-21 化合物在制备用于提高癌症治疗疗效的药物中的用途

Country Status (11)

Country Link
US (3) US6680306B2 (https=)
EP (1) EP1406639A4 (https=)
JP (1) JP2004535430A (https=)
CN (1) CN100558367C (https=)
AU (1) AU2002320140B2 (https=)
BR (1) BR0210550A (https=)
CA (1) CA2451841A1 (https=)
CZ (1) CZ200487A3 (https=)
IL (1) IL159461A0 (https=)
MX (1) MXPA03012021A (https=)
WO (1) WO2003000118A2 (https=)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002072085A1 (en) * 2001-03-14 2002-09-19 Bristol-Myers Squibb Company Combination of epothilone analogs and chemotherapeutic agents for the treatment of proliferative diseases
US6680306B2 (en) * 2001-06-21 2004-01-20 Glycogenesys, Inc. Method for enhancing the effectiveness of cancer therapies
US20030004132A1 (en) * 2001-06-22 2003-01-02 Yan Chang Method and material for treating immune diseases
US6890906B2 (en) 2001-11-21 2005-05-10 Glycogenesys, Inc. Method for controlling angiogenesis in animals
US20040121981A1 (en) * 2001-11-21 2004-06-24 Glycogenesys, Inc. Method for controlling angiogenesis in animals
US20040259816A1 (en) * 2002-10-01 2004-12-23 Pandol Stephen J. Compositions comprising plant-derived polyphenolic compounds and inhibitors of reactive oxygen species and methods of using thereof
US20040223971A1 (en) * 2003-04-07 2004-11-11 Glycogenesys, Inc. Composition and uses of galectin antagonists
WO2004091634A1 (en) * 2003-04-07 2004-10-28 Glycogenesys, Inc. Composition and uses of galectin antagonists
US20050043272A1 (en) * 2003-07-11 2005-02-24 Pro-Pharmaceuticals, Inc. Compositions and methods for hydrophobic drug delivery
DE10335236B3 (de) * 2003-08-01 2005-02-24 Drägerwerk AG Messsystem für die Bestimmung der Konzentration von Propofol (2,6-Diisopropylphenol) im Atemstrom
US20050053664A1 (en) 2003-09-08 2005-03-10 Eliezer Zomer Co-administration of a polysaccharide with a chemotherapeutic agent for the treatment of cancer
EP2591786B1 (en) 2003-10-16 2017-04-12 Cancure Limited Immunomodulating compositions and uses therefor
US20050282773A1 (en) * 2004-01-14 2005-12-22 Pro-Pharmaceuticals, Inc. Modified polysaccharides in combination with anti-cancer drugs for enhanced treatment of cancer
WO2005079314A2 (en) * 2004-02-13 2005-09-01 Pro-Pharmaceuticals, Inc. Compositions and methods used to treat acne and candida
WO2005095463A1 (en) 2004-03-26 2005-10-13 Glycogenesys, Inc. Modified pectins, compositions and methods related thereto
US20060074050A1 (en) * 2004-07-14 2006-04-06 Glycogenesys, Inc. Composition and method for treating hyperproliferative diseases
EP1773128A2 (en) * 2004-08-02 2007-04-18 Pro-Pharmaceuticals, Inc. Compositions and methods for the enhancement of chemotherapy with microbial cytotoxins
KR20070104673A (ko) * 2005-03-23 2007-10-26 화이자 프로덕츠 인코포레이티드 암의 치료를 위한 항－ｃｔｌａ４ 항체와 인돌리논병용요법
US8221803B1 (en) 2007-06-25 2012-07-17 OncoNatural Solutions, Inc. Composition for prostate health
WO2009018447A2 (en) * 2007-07-31 2009-02-05 New York University Diagnostic and treatment methods for characterizing bacterial microbiota in skin conditions
WO2011060272A2 (en) * 2009-11-13 2011-05-19 Dana-Farber Cancer Institute, Inc. Compositions, kits, and methods for the diagnosis, prognosis, monitoring, treatment and modulation of post-transplant lymphoproliferative disorders and hypoxia associated angiogenesis disorders using galectin-1
CA2858601C (en) * 2011-12-08 2020-11-17 Isaac Eliaz Reduction of galectin-3 levels by plasmapheresis
AU2012363033B2 (en) 2011-12-28 2016-06-02 Galectin Therapeutics, Inc. Composition of novel carbohydrate drug for treatment of human diseases
WO2013152313A1 (en) * 2012-04-05 2013-10-10 The Regents Of The University Of California Compositions and methods for treating cancer and diseases and conditions responsive to growth factor inhibition
ES2848538T3 (es) 2012-06-06 2021-08-10 Galectin Therapeutics Inc Composiciones de galacto-ramnogalacturonato para el tratamiento de enfermedades asociadas con elevada óxido nítrico sintasa inducible
DK2900061T3 (da) 2012-09-17 2020-03-02 Galectin Therapeutics Inc Fremgangsmåde til forstærkning af specifikke immunterapier ved cancerbehandling
US8828971B2 (en) 2012-10-10 2014-09-09 Galectin Therapeutics, Inc. Galactose-pronged carbohydrate compounds for the treatment of diabetic nephropathy and associated disorders
US9339515B2 (en) 2013-02-20 2016-05-17 Galectin Therapeutics, Inc. Method for treatment of pulmonary fibrosis
CA2930817A1 (en) 2013-11-17 2015-05-21 Rdd Pharma Ltd. Methods for treating radiation induced gastrointestinal tract injury
AU2017327392B9 (en) 2016-09-13 2023-10-12 Tiziana Life Sciences Plc Dactinomycin compositions and methods for the treatment of myelodysplastic syndrome and acute myeloid leukemia
CA3062648A1 (en) 2017-05-12 2018-11-15 Galectin Sciences, Llc Compounds for the prevention and treatment of diseases and the use thereof
US11633399B2 (en) 2018-12-25 2023-04-25 Sol-Gel Technologies Ltd. Treatment of skin disorders with compositions comprising an EGFR inhibitor

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5895784A (en) * 1994-07-07 1999-04-20 Michigan Cancer Foundation Method for treatment of cancer by oral administration of modified pectin

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US107222A (en) * 1870-09-13 Improvement in machines for tenoning window-sash
US5490991A (en) 1986-07-03 1996-02-13 Advanced Magnetics, Inc. Directed delivery of radioprotectants using a receptor specific carrier
US5843442A (en) 1990-10-22 1998-12-01 Corvas International, Inc. Blood coagulation protein antagonists and uses therefor
US5639737A (en) 1991-11-04 1997-06-17 Co Enzyme Technology Ltd. Method and compositions for treating malignant tumors and inhibiting growth and metastases of malignant tumors
US20020107222A1 (en) 1993-03-01 2002-08-08 David Platt Modified polysaccharides for treatment of cancer
US5490911A (en) * 1993-11-26 1996-02-13 The United States Of America As Represented By The Department Of Energy Reactive multilayer synthesis of hard ceramic foils and films
US5498702A (en) * 1993-12-16 1996-03-12 California Natural Products Treated pectinic acid process and product
US5681923A (en) 1995-10-06 1997-10-28 Platt; David Tumor derived carbohydrate binding protein
EP0888776A4 (en) * 1996-03-15 2005-01-26 Takara Bio Inc PRODUCT OBTAINED BY THERMAL TREATMENT OF URONIC ACID, AND FOOD, BEVERAGES OR MEDICAMENTS CONTAINING THE SAME
US5831052A (en) * 1997-05-07 1998-11-03 Incyte Pharmaceuticals, Inc. New human translocation associated protein
JP2001519366A (ja) * 1997-10-15 2001-10-23 ポーラクス バイオファーマシュティカルズ，インコーポレーテッド ヒ素化合物を用いた、原発性および転移性の腫瘍性疾患を治療するための組成物および方法
US6258383B1 (en) * 1998-08-14 2001-07-10 Lactoferrin Products Company Dietary supplement combining colostrum and lactoferrin in a mucosal delivery format
US6500807B1 (en) * 1999-02-02 2002-12-31 Safescience, Inc. Modified pectin and nucleic acid composition
US6274566B1 (en) * 1999-02-23 2001-08-14 Econugenics, Inc. Methods for treating mammals with modified alginates and pectins
EP1363673A2 (en) 2000-09-25 2003-11-26 Pro-Pharmaceuticals, Inc. Compositions for reducing side effects in chemotherapeutic treatments
US20020104222A1 (en) * 2001-02-06 2002-08-08 Jay Larry Dean Knife for removing the hide of an animal and method therefor
US6914055B2 (en) * 2001-03-27 2005-07-05 Anatole Klyosov Delivery of a therapeutic agent in a formulation for reduced toxicity
US6645946B1 (en) * 2001-03-27 2003-11-11 Pro-Pharmaceuticals, Inc. Delivery of a therapeutic agent in a formulation for reduced toxicity
ES2376739T3 (es) 2001-03-27 2012-03-16 Galectin Therapeutics Inc. Administración conjunta de un polisacárido con un agente quimioterapéutico para el tratamiento del cáncer
US6982255B2 (en) * 2001-03-27 2006-01-03 Anatole Klyosov Delivery of a therapeutic agent in a formulation for reduced toxicity
US6680306B2 (en) * 2001-06-21 2004-01-20 Glycogenesys, Inc. Method for enhancing the effectiveness of cancer therapies
US20040223971A1 (en) * 2003-04-07 2004-11-11 Glycogenesys, Inc. Composition and uses of galectin antagonists
US20060074050A1 (en) * 2004-07-14 2006-04-06 Glycogenesys, Inc. Composition and method for treating hyperproliferative diseases

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5895784A (en) * 1994-07-07 1999-04-20 Michigan Cancer Foundation Method for treatment of cancer by oral administration of modified pectin

Also Published As

Publication number Publication date
CN1543351A (zh) 2004-11-03
EP1406639A4 (en) 2004-07-28
IL159461A0 (en) 2004-06-01
US20040023925A1 (en) 2004-02-05
MXPA03012021A (es) 2004-06-03
US20040043962A1 (en) 2004-03-04
EP1406639A2 (en) 2004-04-14
US6680306B2 (en) 2004-01-20
WO2003000118A2 (en) 2003-01-03
BR0210550A (pt) 2004-05-25
WO2003000118A3 (en) 2003-04-10
JP2004535430A (ja) 2004-11-25
CA2451841A1 (en) 2003-01-03
US20030013681A1 (en) 2003-01-16
AU2002320140B2 (en) 2007-11-29
CZ200487A3 (cs) 2004-10-13

Similar Documents

Publication Publication Date Title
CN100558367C (zh) 化合物在制备用于提高癌症治疗疗效的药物中的用途
AU2002320140A1 (en) Method for enhancing the effectiveness of cancer therapies
Smorenburg et al. The effects of unfractionated heparin on survival in patients with malignancy–a systematic review
SK459890A3 (en) USE OF HYALURONIC ACID, THE SALTS THEREOF AND ANALOGUES FORì (54) PRODUCING A THERAPEUTIC AGENT TO TREAT DISEASES OR CONDIT
Woopen et al. Current and future options in the treatment of malignant ascites in ovarian cancer
JPS62267234A (ja) 悪性腫瘍の転移予防薬
JP5484320B2 (ja) ナリンゲニンとナリンジンを形質転換成長因子−β１のシグナル経路阻害剤とする使用
CN100558368C (zh) 化合物在制备用于治疗免疫性疾病的药物中的用途
CN108186643B (zh) 一种具有协同抗骨肉瘤功效的药物组合物及其应用
AU2012281131B2 (en) Novel zinc finger-like peptide compositions as potent agents in cancer prevention and treatment
JPS6366128A (ja) 動物およびヒト癌の治療に用いられるｃ反応性タンパク質
CN103315981A (zh) 一种联苯二酚和/或其衍生物在制备抑制癌细胞转移药物中的应用
RU2328288C1 (ru) Способ лечения трофических язв нижних конечностей при посттромботической болезни
Pobe et al. Prevention of human bladder tumor cell implantation in an in vitro assay
CN110876803B (zh) 一种包含乳蛋白和油酸的药物组合物
CN1537012A (zh) 长五亚基环ptx3在治疗fgf-8介导的肿瘤疾病中的应用
CN106039309B (zh) 用于治疗恶性肿瘤造成的胸腔积液的药物组合物及其应用
CN111450110A (zh) 牛膝多糖在制备预防非小细胞肺癌转移药物中的应用
CN118236380B (zh) 盐酸布那唑嗪在防治肠缺血再灌注损伤中的应用
Uhlenbruck et al. Prevention of experimental liver metastases by D-galactose
CN101130087A (zh) 腹腔化疗用药物载体溶液及药物组合物
US20060148681A1 (en) Method for treating tumor and/or preventing tumor metastasis and relapse
CN116115635A (zh) 低分子柑橘果胶单独或联合铂类药物在制备抗肿瘤产品中的应用
WO2022008890A1 (en) Cancer treatment
CN118903431A (zh) Itgb4/bnip3信号轴阻断剂在制备胰腺癌免疫治疗药物中的应用

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
ASS Succession or assignment of patent right

Owner name: MARBOROUGH RESEARCH CO., LTD.

Free format text: FORMER OWNER: GRIECO GENE SYSTEMS, INC.

Effective date: 20080912

C41 Transfer of patent application or patent right or utility model
TA01 Transfer of patent application right

Effective date of registration: 20080912

Address after: Massachusetts

Applicant after: Mar Polo research

Address before: Massachusetts

Applicant before: Glycogenesys Inc.

C14 Grant of patent or utility model
GR01 Patent grant
C17 Cessation of patent right
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20091111

Termination date: 20100621